Yescarta More Cost-Effective Compared to Kymriah but With Higher CRS and NT Rates; Updated Results From Kymriah’s Ph1b PORTIA Trial; POC CD19 CAR-Ts Outperform OOS Kymriah; EHA 2021 Day 1

On the first day of EHA 2021, seven key clinical updates were presented from Novartis, Gilead, the Sheba Medical Center, and the Fred Hutchinson Cancer Center. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.